To view all submissions (2011 to present) HepCBC has made to either CADTH (to determine if drug should be allowed for sale in Canada for a specific purpose) and BC Pharmacare (to determine if drug should be covered/purchase reimbursed by Pharmacare) please see this updated link: http://hepcbc.ca/patient-group-submissions-bc-pharmacare-cadth/
The HCV Manifesto can now be signed online by individuals and groups. Our target is 1000 individuals and 200 groups. READ and SIGN the PETITION at www.hepcbc/hcv-manifesto/; THANKS!
Sofosbuvir (trade name Sovaldi) has now been approved for use in Canada. There will still be many months before it is approved for coverage by your provincial Pharmacare plan. But meanwhile, if you are in great need of this drug but fear you cannot afford it, consider applying to Gilead Sciences compassionate care's Momentum Support Program™ or their Sovaldi Co-pay assistance program. See details in complete Gilead Sciences Press Release below. ### HEALTH
AbbVie Inc's all-oral, 12-week hepatitis C therapy cured 96 percent of 394 Genotype 1 patients, half of whom were previous `null responders` to standard treatment of pegylated interferon-ribavirin. More information below... from Yahoo HEREhttp://ca.news.yahoo.com/abbvie-says-96-percent-patients-oral-hepatitis-c-133448285--finance.html and from AbbVie HEREhttp://abbvie.mediaroom.com/2013-12-10-AbbVie-Demonstrates-96-percent-SVR-12-in-its-Phase-III-Study-of
Simeprevir (trade name Galexos) has now been approved for use in Canada. It is a once-daily pill which is taken along with ribavirin and pegylated interferon alfa to treat hepatitis C genotype 1 in a "triple therapy." There will still be many months before it is approved for coverage by your provincial Pharmacare plan. See details in complete Janssen Inc. Press Release below. ### New Treatment for Hepatitis C Approved by Health Canada Priority Review Give
Whether you're a medical professional or a patient who likes "more details", download this great resource:http://pdf.flyingpublisher.com/HepatitisC_Guide_2013.pdf